ImmunoPrecise Antibodies Ltd. Total Liabilities
ImmunoPrecise Antibodies Ltd. total liabilities. Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) has total liabilities worth $8.40 Million USD as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ImmunoPrecise Antibodies Ltd. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ImmunoPrecise Antibodies Ltd. (1997–2025)
Total liabilities of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. This chart illustrates how ImmunoPrecise Antibodies Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore HYFT long-term investment intensity to see how much of total assets are deployed in long-term investments.
ImmunoPrecise Antibodies Ltd. Competitors by Total Liabilities
The table below lists competitors of ImmunoPrecise Antibodies Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Battery Mineral Resources Corp
V:BMR
|
Canada | CA$67.33 Million |
|
Erciyas Celik Boru Sanayi A.S.
IS:ERCB
|
Turkey | TL11.01 Billion |
|
flyExclusive, Inc.
NYSE:FLYX
|
USA | $496.04 Million |
|
Naturel Yenilenebilir Enerji Ticare
IS:NATEN
|
Turkey | TL8.02 Billion |
|
DDC Enterprise Limited
NYSE MKT:DDC
|
USA | $843.97 Million |
|
Marketwise Inc
NASDAQ:MKTW
|
USA | $453.14 Million |
|
Pangaea Oncology S.A.
MC:PANG
|
Spain | €10.05 Million |
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
China | HK$938.16 Million |
Liability Composition Analysis (1997–2025)
This chart breaks down ImmunoPrecise Antibodies Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HYFT total assets.
Liquidity & Leverage Metrics
ImmunoPrecise Antibodies Ltd. Total Liabilities Ratios Explained
ImmunoPrecise Antibodies Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImmunoPrecise Antibodies Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual total liabilities of ImmunoPrecise Antibodies Ltd. from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $20.82 Million | -20.15% |
| 2024-04-30 | $26.07 Million | +30.27% |
| 2023-04-30 | $20.01 Million | +8.98% |
| 2022-04-30 | $18.36 Million | +82.98% |
| 2021-04-30 | $10.04 Million | -17.59% |
| 2020-04-30 | $12.18 Million | +18.49% |
| 2019-04-30 | $10.28 Million | -13.44% |
| 2018-04-30 | $11.87 Million | +1318.60% |
| 2017-04-30 | $836.91K | +77.26% |
| 2016-04-30 | $472.15K | +85.42% |
| 2015-04-30 | $254.64K | -16.10% |
| 2014-04-30 | $303.50K | +14.26% |
| 2013-04-30 | $265.63K | +24.65% |
| 2012-04-30 | $213.10K | +150.14% |
| 2011-04-30 | $85.19K | -15.21% |
| 2010-04-30 | $100.47K | -33.39% |
| 2009-04-30 | $150.84K | +302.67% |
| 2008-04-30 | $37.46K | -75.96% |
| 2007-04-30 | $155.85K | +12.43% |
| 2006-04-30 | $138.62K | +193.83% |
| 2005-04-30 | $47.18K | -5.49% |
| 2004-04-30 | $49.92K | +211.57% |
| 2003-04-30 | $16.02K | -91.47% |
| 2002-04-30 | $187.72K | -79.07% |
| 2001-04-30 | $896.75K | +8770.78% |
| 2000-04-30 | $10.11K | -71.75% |
| 1999-04-30 | $35.78K | -46.90% |
| 1998-04-30 | $67.39K | -73.05% |
| 1997-04-30 | $250.04K | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more